Skip to content
MRD Watch

Wednesday, November 18, 2026

Subscribe
Sponsor this briefing. One site and newsletter slot, $250/week.

Briefing

Personalized Detection of Circulating Tumor DNA Antedates Breast Cancer Metastatic Recurrence.

Personalized assays targeting 16 variants chosen from the primary tumor whole exome were used on plasma collected every 6 months for up to 4 years to detect ctDNA before metastatic breast cancer recurrence. The abstract does not name a commercial assay.

Clinical Cancer ResearchPubMed 30992300DOI 10.1158/1078-0432.CCR-18-3663